Neurones (ENXTPA:NRO) Stock Price Drifts Below Stronger Earnings And Fair Value

Neurones shares have drifted over the past month, yet today’s earnings dropped a quiet challenge to that caution. The stock closed at €36.25 after a soft 30 day move, while the business posted H1 2026 revenue of €454.8m and trailing 12 month earnings from continuing operations of €66.3m. The real flashpoint is valuation. A P/E of 15.7x and a discounted cash flow estimate of €41.09 create a gap that traders appear to be testing against their nerves rather than the numbers.

Love that Neurones is printing solid earnings with a P/E below its own cash flow estimate signal, but uneasy about whether this gap is a value opportunity or a trap. Benchmark it against 181 high quality undervalued stocks to see how it stacks up against other cash generative, fundamentally strong ideas.

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): €454.8m vs. €424.26m (up about 7.2%)
• Net Income, excl. extra items (H1 2026 vs. H1 2025): €25.9m vs. €22.683m (up about 14.2%)
• Basic EPS (H1 2026 vs. H1 2025): Not disclosed for H1 2026 vs. €0.9342 in H1 2025 (no direct percentage comparison possible)
• Net Profit Margin, trailing 12 months (2026 vs. 2025): 6.2% vs. 6.1% (modest improvement)

Prefer clear charts over another wall of figures on Neurones? See the full visual breakdown of the business, with its valuation front and center, via our company report for Neurones.

Neurones results lean toward cautious optimism

For anyone leaning bullish on Neurones as a steady digital transformation partner, these figures help. Revenue of €454.8m for H1 2026 versus €424.26m a year earlier and higher net income of €25.9m versus €22.683m both point in the same direction. A slightly stronger trailing net profit margin at 6.2% versus 6.1% hints that the model is not just growing in size, but holding its line on profitability as well.

Short term share drift keeps risk questions alive

Bears will point to the recent share price drift. The stock is down about 6.5% over 30 days, even with revenue and earnings moving higher on a yearly comparison. That disconnect keeps questions around competitive pressure and contract visibility firmly on the table. At the same time, a 90 day gain of roughly 2.7% suggests recent weakness is not yet a clear verdict against the business trajectory.

Reveal whether Neurones’ steady revenue gains and firmer margins have analysts raising or cutting their expectations. Compare that operational story with the street’s projected upside in the consensus price target analysis for Neurones.

Stay Ahead Of Your Next Move

If Neurones’ mix of a 15.7x P/E and a discounted cash flow estimate of €41.09 has you watching that valuation gap, register for free with Simply Wall St and add it to your Watchlist to track share price moves against fair value and wait for a level that fits your plan. Once you own it, use the Portfolio Command Center to cut through short term volatility and focus on the key developments that matter to your holdings. Over time, compare your own thesis with thousands of other investors through the Community so you see different angles on the same set of numbers. That way you spot potential catalysts and emerging risks early and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Before The Crowd Moves

Fresh ideas move first. Stalled tickers can be left behind when money chases breakout momentum, and quiet winners are sometimes caught flying higher under the radar. Consider researching early.

• Explore potential momentum shifts by scouting curated 98 resilient stocks with low risk scores that aim to keep downside contained while you focus on upside stories still taking shape.
• Look for income that might continue even when prices wobble by scanning hand picked 165 dividend fortresses built around sturdier balance sheets.
• Review selected 91 nuclear energy infrastructure stocks that sit at the junction of energy demand, infrastructure spending and long term capital flows for future-facing exposure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com